Amesite Q3 Revenue Soars 171% to $83K, EPS Loss Narrows to $0.15
summarizeSummary
Amesite Inc. reported third-quarter 2026 results, showing revenue of $83.33K, a significant 171.5% increase year-over-year, and a diluted loss per share of ($0.15), which slightly improved from ($0.16) in the prior-year quarter. This news provides specific financial details from the 10-Q filing that was reported minutes earlier in the timeline, which also highlighted a $2.6 million capital raise and efforts to regain Nasdaq compliance, alongside potential substantial dilution. For a micro-cap company trading near its 52-week low, the substantial percentage growth in revenue indicates early commercial traction and could be a positive signal for investors. However, the company remains unprofitable with a net loss of ($678.06K), and the ongoing dilution from recent capital raises and S-1 filings remains a significant concern. Investors will monitor whether the company can sustain its revenue growth, improve profitability, and manage its cash burn effectively, especially with its strategic shift to healthcare and the NurseMagic™ product.
At the time of this announcement, AMST was trading at $0.79 on NASDAQ in the Technology sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.77 to $4.78. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.